ETORICOXIB 60MG + PARACETAMOL 325MG TABLETS are a combination oral solid dosage formulation containing Etoricoxib 60 mg and Paracetamol 325 mg as active pharmaceutical ingredients. Developing a dual-active tablet requires careful evaluation of API compatibility, particle characteristics, blend uniformity, compression behaviour and finished-product stability. Since both ingredients have different physicochemical properties, the formulation and manufacturing process should be optimized to achieve consistent distribution and reproducible tablet quality. For pharmaceutical companies expanding a PCD Pharma Franchise portfolio, this combination can be incorporated into a professionally structured oral solid dosage range with standardized specifications.
The specified composition contains Etoricoxib 60 mg and Paracetamol 325 mg per tablet. During formulation development, both active pharmaceutical ingredients are evaluated individually and together to establish their compatibility with the proposed excipient system.
Depending on the selected manufacturing technology, the formulation may contain suitable diluents, binders, disintegrants, glidants and lubricants. Each excipient is selected based on its functional role and compatibility with the two active ingredients.
Preformulation studies may evaluate particle-size distribution, bulk density, flowability, moisture characteristics and compressibility. Compatibility studies can also be performed to identify potential interactions between Etoricoxib, Paracetamol and the selected excipients.
The formulation development objective is to establish a stable powder system capable of producing tablets with consistent weight, mechanical strength, disintegration and dissolution characteristics.
Uniform distribution of both active ingredients is a critical consideration during production. Etoricoxib and Paracetamol can differ in particle size, density and flow characteristics, which may influence the behaviour of the final powder blend.
Raw materials are first subjected to appropriate identification and quality checks. Depending on the physical characteristics of the ingredients, sieving, milling or other particle-size management techniques may be considered.
A controlled blending sequence can be established during process development. Premixing of Etoricoxib with a selected portion of the excipient matrix may be considered where necessary to support uniform distribution.
The final blending stage should be controlled for equipment type, batch loading, mixing speed and processing time. Excessive post-blending movement should also be minimized because powder segregation can occur during inappropriate handling.
Representative samples may be collected from different locations within the blend and analyzed using suitable validated methods. Blend-uniformity testing provides supporting evidence that both active ingredients are consistently distributed before compression.
After the blend satisfies predefined in-process requirements, it can proceed to tablet compression using suitable pharmaceutical equipment. Compression parameters are established according to the formulation's flow and compaction characteristics.
Variables such as compression force, turret speed, feeder settings and tooling configuration can influence tablet weight, thickness, hardness and friability. These parameters are therefore optimized during formulation and process development.
In-process checks may include tablet appearance, weight variation, thickness and hardness at defined intervals. Friability testing can provide information regarding the mechanical strength of the finished tablets and their ability to withstand handling.
The formulation may be manufactured as an uncoated or film-coated tablet depending on the finalized product design. If a coating system is used, coating suspension properties, spray rate, drying conditions and coating uniformity are controlled within established limits.
Process validation can help demonstrate that the selected manufacturing parameters are capable of consistently producing tablets that meet predefined specifications.
Quality control of ETORICOXIB 60MG + PARACETAMOL 325MG TABLETS involves chemical, physical and performance-related testing of the finished product.
Validated analytical procedures can be used for identification and quantitative determination of both Etoricoxib and Paracetamol. Since two active ingredients are present, analytical methods should provide suitable selectivity and accuracy for individual component measurement.
Physical testing may include appearance, average weight, weight variation, thickness, hardness, friability and disintegration. Dissolution testing can be performed under specified laboratory conditions to evaluate the release characteristics of both active ingredients.
Dosage-unit uniformity testing may be incorporated where required by the finalized product specification. This helps evaluate consistency among individual tablets.
Related substances and degradation products may also be monitored as part of the analytical quality-control program. Method validation should establish suitable specificity, accuracy, precision, linearity and robustness for the intended testing procedure.
These quality-control activities, combined with appropriate in-process monitoring, help support consistent manufacturing and reproducible finished-product characteristics.
Stability studies are conducted to evaluate whether ETORICOXIB 60MG + PARACETAMOL 325MG TABLETS maintain their specified quality characteristics throughout the proposed shelf life.
Depending on the finalized product specification, stability testing may monitor appearance, assay, dissolution, degradation-related parameters, moisture characteristics and other applicable attributes.
Packaging selection should provide suitable protection against environmental exposure during storage and transportation. Blister packs, strip packs or other pharmaceutical-grade packaging systems may be considered according to the stability profile of the formulation.
Moisture-barrier properties can be evaluated where relevant. Compatibility studies may also assess whether the formulation interacts with the primary packaging material over time.
Stability studies should preferably be performed using the final commercial packaging configuration. The resulting data can support establishment of suitable storage conditions and the proposed shelf life.
The final pack should maintain tablet integrity and include accurate product identification, composition, strength, batch details, manufacturing information, expiry information and applicable storage instructions according to approved requirements.
ETORICOXIB 60MG + PARACETAMOL 325MG TABLETS can be incorporated into a diversified pharmaceutical portfolio containing combination tablets, single-ingredient formulations, capsules and other oral dosage forms. Standardized specifications, consistent manufacturing procedures and professional packaging can support efficient product portfolio management.
For a PCD Pharma Franchise portfolio, the product can be presented with accurate composition, strength, packing configuration, manufacturer details and other approved product information. Packaging artwork and promotional material should correspond with the finalized formulation and applicable regulatory requirements.
The product-development pathway includes raw-material qualification, preformulation, API-excipient compatibility studies, particle-size management, controlled blending, compression optimization, analytical testing, dissolution evaluation, stability assessment and packaging selection.
Overall, ETORICOXIB 60MG + PARACETAMOL 325MG TABLETS represent a dual-active oral solid dosage formulation requiring precise control of material characteristics and manufacturing parameters. Appropriate blend-uniformity evaluation, optimized compression, validated analytical testing, dissolution assessment, protective packaging and stability monitoring can collectively support consistent product quality and effective integration into a professional pharmaceutical and PCD Pharma Franchise product portfolio.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech